Compare · MVIS vs TMO
MVIS vs TMO
Side-by-side comparison of MicroVision Inc. (MVIS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MVIS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $183.61B, about 1541.0x MVIS ($119.1M).
- Over the past year, MVIS is down 70.6% and TMO is up 19.2% - TMO leads by 89.8 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 12 for MVIS).
- TMO has more recent analyst coverage (25 ratings vs 2 for MVIS).
- Company
- MicroVision Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.36-6.96%
- $494.20+5.25%
- Market cap
- $119.1M
- $183.61B
- 1M return
- -46.66%
- +6.28%
- 1Y return
- -70.63%
- +19.22%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- News (4w)
- 12
- 17
- Recent ratings
- 2
- 25
MicroVision Inc.
MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was incorporated in 1993 and is headquartered in Redmond, Washington.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MVIS
- Interim CFO Hrynewich Stephen covered exercise/tax liability with 2,017 shares and converted options into 6,000 shares, increasing direct ownership by 2% to 182,497 units (SEC Form 4) to satisfy tax liability
- Director Smith Jada converted options into 22,007 shares, increasing direct ownership by 14% to 176,550 units (SEC Form 4)
- Director Schabert Peter converted options into 22,007 shares, increasing direct ownership by 15% to 168,478 units (SEC Form 4)
- GC Markham Drew G converted options into 119,880 shares and covered exercise/tax liability with 35,901 shares, increasing direct ownership by 22% to 472,308 units (SEC Form 4) to cover withholding tax
- Executive Vice Chair Biddiscombe Simon converted options into 22,007 shares, increasing direct ownership by 6% to 407,256 units (SEC Form 4)
- Director Peterson Laura J. converted options into 18,005 shares, increasing direct ownership by 20% to 109,601 units (SEC Form 4)
- Director Carlile Robert Paul converted options into 22,007 shares, increasing direct ownership by 4% to 560,706 units (SEC Form 4)
- Director Herbst Jeffrey A converted options into 22,007 shares, increasing direct ownership by 8% to 280,919 units (SEC Form 4)
- SEC Form PRE 14A filed by MicroVision Inc.
- MicroVision Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)